Cargando…
Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions
BACKGROUND: People living with chronic disease, particularly seniors (≥60 years old), made up of most severe symptom and death cases among SARS-CoV-2 infected patients. However, they are lagging behind in the national COVID-19 vaccination campaign in China due to the uncertainty of vaccine safety an...
Autores principales: | Li, Chunmei, Bi, Hanfang, Fu, Zhenwang, Li, Ao, Wan, Na, Hu, Jun, Yang, Fan, Zhou, Tai-Cheng, Liang, Yupeng, Su, Wei, Shi, Tianpei, Yang, Mei, Wang, Rong, Qin, Wanting, Yu, Xuanjing, Zheng, Hong-Yi, Zhou, Zumi, Zheng, Yong-Tang, Wei, Jia, Zeng, Gang, Zhang, Zijie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700702/ https://www.ncbi.nlm.nih.gov/pubmed/36434092 http://dx.doi.org/10.1038/s43856-022-00216-2 |
Ejemplares similares
-
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
por: Zhang, Yuemiao, et al.
Publicado: (2022) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023) -
Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022) -
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022) -
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)